Does Dr. STEVEN POTTER have financial conflicts of interest?

Dr. STEVEN POTTER (M.D.) has received a total of $27,248 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $27,248 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. STEVEN POTTER?

According to CMS Open Payments data, Dr. STEVEN POTTER received funding from TAKEDA PHARMACEUTICALS U.S.A ($13,592), VERTEX PHARMACEUTICALS INCORPORATED ($9,957), and VELOXIS PHARMACEUTICALS ($3,441).

Does Dr. STEVEN POTTER receive research grants or speaking fees?

Dr. STEVEN POTTER has received $27,248 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. STEVEN POTTER

M.D.Real-Time Hydrated

Specialty: Transplant Surgery

Practice Location: WASHINGTON, DC 20007

NPI Number: 1376595298

LIFETIME INDUSTRY VALUE

$27,248

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. POTTER is a verified Transplant Surgery practitioner based in WASHINGTON, DC.

Between 2021 and 2025, Dr. POTTER had an overall industry promotional and research financial footprint of $27,248 as recorded in the federal CMS Open Payments database.

$27,248 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. POTTER's primary funding source is TAKEDA PHARMACEUTICALS U.S.A, which accounts for $13,592 (representing 49.9% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

TAKEDA PHARMACEUTICALS U.S.A

Rank 1

$13,592

49.9%

VERTEX PHARMACEUTICALS INCORPORATED

Rank 2

$9,957

36.5%

VELOXIS PHARMACEUTICALS

Rank 3

$3,441

12.6%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.